Pharmaceutical economics and policy /:
The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its a...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford ; New York :
Oxford University Press,
2007.
|
| Ausgabe: | 2nd ed. |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care |
| Beschreibung: | 1 online resource (xiv, 336 pages) : illustrations |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9780199719747 0199719748 |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBU-ocn710992761 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 110404s2007 enka ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e pn |c N$T |d OCLCE |d E7B |d OCLCQ |d YDXCP |d EBLCP |d OCLCQ |d OCLCF |d OCLCQ |d NLGGC |d OCLCO |d OCLCQ |d AZK |d AGLDB |d OCLCQ |d MOR |d OCLCO |d LIP |d PIFAG |d ZCU |d OCLCO |d MERUC |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d U3W |d OCLCA |d KIJ |d STF |d WRM |d OCLCQ |d NRAMU |d OCLCA |d ICG |d OCLCO |d VT2 |d AU@ |d OCLCQ |d WYU |d OCLCA |d DKC |d OCLCO |d OCLCQ |d UX1 |d OCLCQ |d OCLCA |d UKCRE |d BOL |d INARC |d OCLCA |d UKAHL |d OCLCQ |d OCLCO |d OCLCQ |d YDX |d OCLCO |d OCLCL | ||
| 015 | |a GBA671631 |2 bnb | ||
| 016 | 7 | |a 101266298 |2 DNLM | |
| 016 | 7 | |a 013536538 |2 Uk | |
| 019 | |a 655158139 |a 764556838 |a 961507590 |a 962574829 |a 988487185 |a 990480256 |a 992111859 |a 1037719374 |a 1038614021 |a 1045446806 |a 1055330858 |a 1058438568 |a 1064153338 |a 1081285735 |a 1114478375 |a 1153540473 |a 1194917605 |a 1228535532 | ||
| 020 | |a 9780199719747 |q (electronic bk.) | ||
| 020 | |a 0199719748 |q (electronic bk.) | ||
| 020 | |z 0195300955 | ||
| 020 | |z 9780195300956 | ||
| 035 | |a (OCoLC)710992761 |z (OCoLC)655158139 |z (OCoLC)764556838 |z (OCoLC)961507590 |z (OCoLC)962574829 |z (OCoLC)988487185 |z (OCoLC)990480256 |z (OCoLC)992111859 |z (OCoLC)1037719374 |z (OCoLC)1038614021 |z (OCoLC)1045446806 |z (OCoLC)1055330858 |z (OCoLC)1058438568 |z (OCoLC)1064153338 |z (OCoLC)1081285735 |z (OCoLC)1114478375 |z (OCoLC)1153540473 |z (OCoLC)1194917605 |z (OCoLC)1228535532 | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a HD9666.5 |b .S385 2007eb | |
| 060 | 4 | |a QV 736 |b S413p 2007 | |
| 072 | 7 | |a BUS |x 070130 |2 bisacsh | |
| 082 | 7 | |a 338.4/761510973 |2 22 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Schweitzer, Stuart O. |0 http://id.loc.gov/authorities/names/n78073894 | |
| 245 | 1 | 0 | |a Pharmaceutical economics and policy / |c Stuart O. Schweitzer. |
| 250 | |a 2nd ed. | ||
| 260 | |a Oxford ; |a New York : |b Oxford University Press, |c 2007. | ||
| 300 | |a 1 online resource (xiv, 336 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 340 | |g polychrome. |2 rdacc |0 http://rdaregistry.info/termList/RDAColourContent/1003 | ||
| 347 | |a text file |2 rdaft |0 http://rdaregistry.info/termList/fileType/1002 | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead. | |
| 520 | |a The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care | ||
| 588 | 0 | |a Print version record. | |
| 650 | 0 | |a Pharmaceutical industry |z United States. | |
| 650 | 0 | |a Pharmaceutical policy |z United States. | |
| 650 | 0 | |a Pharmaceutical industry. | |
| 650 | 1 | 2 | |a Economics, Pharmaceutical |
| 650 | 2 | 2 | |a Drug Industry |
| 650 | 2 | 2 | |a Public Policy |
| 651 | 2 | |a United States | |
| 650 | 6 | |a Industrie pharmaceutique |z États-Unis. | |
| 650 | 6 | |a Médicaments |x Politique gouvernementale |z États-Unis. | |
| 650 | 6 | |a Industrie pharmaceutique. | |
| 650 | 6 | |a Pharmacoéconomie. | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Industries |x Pharmaceutical & Biotechnology. |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 776 | 0 | 8 | |i Print version: |a Schweitzer, Stuart O. |t Pharmaceutical economics and policy. |b 2nd ed. |d Oxford ; New York : Oxford University Press, 2007 |z 0195300955 |w (DLC) 2006003075 |w (OCoLC)63277820 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBU |q FWS_PDA_EBU |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=191561 |3 Volltext |
| 938 | |a YBP Library Services |b YANK |n 20447682 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH28533167 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH24087193 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL886688 | ||
| 938 | |a ebrary |b EBRY |n ebr10460685 | ||
| 938 | |a EBSCOhost |b EBSC |n 191561 | ||
| 938 | |a Internet Archive |b INAR |n pharmaceuticalec0000schw_n2g7 | ||
| 938 | |a YBP Library Services |b YANK |n 3875136 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBU | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBU-ocn710992761 |
|---|---|
| _version_ | 1816796901076369408 |
| adam_text | |
| any_adam_object | |
| author | Schweitzer, Stuart O. |
| author_GND | http://id.loc.gov/authorities/names/n78073894 |
| author_facet | Schweitzer, Stuart O. |
| author_role | |
| author_sort | Schweitzer, Stuart O. |
| author_variant | s o s so sos |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | H - Social Science |
| callnumber-label | HD9666 |
| callnumber-raw | HD9666.5 .S385 2007eb |
| callnumber-search | HD9666.5 .S385 2007eb |
| callnumber-sort | HD 49666.5 S385 42007EB |
| callnumber-subject | HD - Industries, Land Use, Labor |
| collection | ZDB-4-EBU |
| contents | The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead. |
| ctrlnum | (OCoLC)710992761 |
| dewey-full | 338.4/761510973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/761510973 |
| dewey-search | 338.4/761510973 |
| dewey-sort | 3338.4 9761510973 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| edition | 2nd ed. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06322cam a2200769 a 4500</leader><controlfield tag="001">ZDB-4-EBU-ocn710992761</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">110404s2007 enka ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">OCLCE</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">YDXCP</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">NLGGC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AZK</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">MOR</subfield><subfield code="d">OCLCO</subfield><subfield code="d">LIP</subfield><subfield code="d">PIFAG</subfield><subfield code="d">ZCU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">U3W</subfield><subfield code="d">OCLCA</subfield><subfield code="d">KIJ</subfield><subfield code="d">STF</subfield><subfield code="d">WRM</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">NRAMU</subfield><subfield code="d">OCLCA</subfield><subfield code="d">ICG</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VT2</subfield><subfield code="d">AU@</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">WYU</subfield><subfield code="d">OCLCA</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UX1</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">UKCRE</subfield><subfield code="d">BOL</subfield><subfield code="d">INARC</subfield><subfield code="d">OCLCA</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">YDX</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBA671631</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">101266298</subfield><subfield code="2">DNLM</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">013536538</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">655158139</subfield><subfield code="a">764556838</subfield><subfield code="a">961507590</subfield><subfield code="a">962574829</subfield><subfield code="a">988487185</subfield><subfield code="a">990480256</subfield><subfield code="a">992111859</subfield><subfield code="a">1037719374</subfield><subfield code="a">1038614021</subfield><subfield code="a">1045446806</subfield><subfield code="a">1055330858</subfield><subfield code="a">1058438568</subfield><subfield code="a">1064153338</subfield><subfield code="a">1081285735</subfield><subfield code="a">1114478375</subfield><subfield code="a">1153540473</subfield><subfield code="a">1194917605</subfield><subfield code="a">1228535532</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780199719747</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0199719748</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0195300955</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780195300956</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)710992761</subfield><subfield code="z">(OCoLC)655158139</subfield><subfield code="z">(OCoLC)764556838</subfield><subfield code="z">(OCoLC)961507590</subfield><subfield code="z">(OCoLC)962574829</subfield><subfield code="z">(OCoLC)988487185</subfield><subfield code="z">(OCoLC)990480256</subfield><subfield code="z">(OCoLC)992111859</subfield><subfield code="z">(OCoLC)1037719374</subfield><subfield code="z">(OCoLC)1038614021</subfield><subfield code="z">(OCoLC)1045446806</subfield><subfield code="z">(OCoLC)1055330858</subfield><subfield code="z">(OCoLC)1058438568</subfield><subfield code="z">(OCoLC)1064153338</subfield><subfield code="z">(OCoLC)1081285735</subfield><subfield code="z">(OCoLC)1114478375</subfield><subfield code="z">(OCoLC)1153540473</subfield><subfield code="z">(OCoLC)1194917605</subfield><subfield code="z">(OCoLC)1228535532</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">HD9666.5</subfield><subfield code="b">.S385 2007eb</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 736</subfield><subfield code="b">S413p 2007</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">BUS</subfield><subfield code="x">070130</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">338.4/761510973</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schweitzer, Stuart O.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n78073894</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical economics and policy /</subfield><subfield code="c">Stuart O. Schweitzer.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2nd ed.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Oxford ;</subfield><subfield code="a">New York :</subfield><subfield code="b">Oxford University Press,</subfield><subfield code="c">2007.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xiv, 336 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="340" ind1=" " ind2=" "><subfield code="g">polychrome.</subfield><subfield code="2">rdacc</subfield><subfield code="0">http://rdaregistry.info/termList/RDAColourContent/1003</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="2">rdaft</subfield><subfield code="0">http://rdaregistry.info/termList/fileType/1002</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Economics, Pharmaceutical</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Drug Industry</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Public Policy</subfield></datafield><datafield tag="651" ind1=" " ind2="2"><subfield code="a">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Politique gouvernementale</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pharmacoéconomie.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS</subfield><subfield code="x">Industries</subfield><subfield code="x">Pharmaceutical & Biotechnology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Schweitzer, Stuart O.</subfield><subfield code="t">Pharmaceutical economics and policy.</subfield><subfield code="b">2nd ed.</subfield><subfield code="d">Oxford ; New York : Oxford University Press, 2007</subfield><subfield code="z">0195300955</subfield><subfield code="w">(DLC) 2006003075</subfield><subfield code="w">(OCoLC)63277820</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBU</subfield><subfield code="q">FWS_PDA_EBU</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=191561</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">20447682</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH28533167</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH24087193</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL886688</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10460685</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">191561</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Internet Archive</subfield><subfield code="b">INAR</subfield><subfield code="n">pharmaceuticalec0000schw_n2g7</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">3875136</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBU</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| geographic | United States United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq |
| geographic_facet | United States |
| id | ZDB-4-EBU-ocn710992761 |
| illustrated | Illustrated |
| indexdate | 2024-11-26T14:49:02Z |
| institution | BVB |
| isbn | 9780199719747 0199719748 |
| language | English |
| oclc_num | 710992761 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xiv, 336 pages) : illustrations |
| psigel | ZDB-4-EBU |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Oxford University Press, |
| record_format | marc |
| spelling | Schweitzer, Stuart O. http://id.loc.gov/authorities/names/n78073894 Pharmaceutical economics and policy / Stuart O. Schweitzer. 2nd ed. Oxford ; New York : Oxford University Press, 2007. 1 online resource (xiv, 336 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier polychrome. rdacc http://rdaregistry.info/termList/RDAColourContent/1003 text file rdaft http://rdaregistry.info/termList/fileType/1002 Includes bibliographical references and index. The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead. The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care Print version record. Pharmaceutical industry United States. Pharmaceutical policy United States. Pharmaceutical industry. Economics, Pharmaceutical Drug Industry Public Policy United States Industrie pharmaceutique États-Unis. Médicaments Politique gouvernementale États-Unis. Industrie pharmaceutique. Pharmacoéconomie. BUSINESS & ECONOMICS Industries Pharmaceutical & Biotechnology. bisacsh Pharmaceutical industry fast Pharmaceutical policy fast United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq Print version: Schweitzer, Stuart O. Pharmaceutical economics and policy. 2nd ed. Oxford ; New York : Oxford University Press, 2007 0195300955 (DLC) 2006003075 (OCoLC)63277820 FWS01 ZDB-4-EBU FWS_PDA_EBU https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=191561 Volltext |
| spellingShingle | Schweitzer, Stuart O. Pharmaceutical economics and policy / The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead. Pharmaceutical industry United States. Pharmaceutical policy United States. Pharmaceutical industry. Economics, Pharmaceutical Drug Industry Public Policy Industrie pharmaceutique États-Unis. Médicaments Politique gouvernementale États-Unis. Industrie pharmaceutique. Pharmacoéconomie. BUSINESS & ECONOMICS Industries Pharmaceutical & Biotechnology. bisacsh Pharmaceutical industry fast Pharmaceutical policy fast |
| title | Pharmaceutical economics and policy / |
| title_auth | Pharmaceutical economics and policy / |
| title_exact_search | Pharmaceutical economics and policy / |
| title_full | Pharmaceutical economics and policy / Stuart O. Schweitzer. |
| title_fullStr | Pharmaceutical economics and policy / Stuart O. Schweitzer. |
| title_full_unstemmed | Pharmaceutical economics and policy / Stuart O. Schweitzer. |
| title_short | Pharmaceutical economics and policy / |
| title_sort | pharmaceutical economics and policy |
| topic | Pharmaceutical industry United States. Pharmaceutical policy United States. Pharmaceutical industry. Economics, Pharmaceutical Drug Industry Public Policy Industrie pharmaceutique États-Unis. Médicaments Politique gouvernementale États-Unis. Industrie pharmaceutique. Pharmacoéconomie. BUSINESS & ECONOMICS Industries Pharmaceutical & Biotechnology. bisacsh Pharmaceutical industry fast Pharmaceutical policy fast |
| topic_facet | Pharmaceutical industry United States. Pharmaceutical policy United States. Pharmaceutical industry. Economics, Pharmaceutical Drug Industry Public Policy United States Industrie pharmaceutique États-Unis. Médicaments Politique gouvernementale États-Unis. Industrie pharmaceutique. Pharmacoéconomie. BUSINESS & ECONOMICS Industries Pharmaceutical & Biotechnology. Pharmaceutical industry Pharmaceutical policy |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=191561 |
| work_keys_str_mv | AT schweitzerstuarto pharmaceuticaleconomicsandpolicy |